Speakers

Expand/Collapse

Michael Tolentino
Co-Founder and Chief Technology Officer
Aviceda Therapeutics

A retinal surgeon, researcher, clinical trialist, and biotech entrepreneur. As a member of the Folkman lab at Harvard Medical School, he demonstrated that Vascular Endothelial Growth Factor (VEGF) is necessary and sufficient in macular degeneration and diabetic retinopathy. He also pre-clinically developed the use of eye injections for macular degeneration and diabetic retinopathy. His research formed the basis for the development of Intravitreal VEGFS. His early purification work on Avastin permitted its use as an off-label eye injection in retinal diseases. At the University of Pennsylvania, he invented Bevasiranib, a first generation small interfering RNA (siRNA) against VEGF-A representing the first RNA interference therapeutic to enter clinical trials. This technology allowed him to co-found Acuity Pharmaceuticals which became OPKO health (Nasdaq: OPK). After his exit from OPKO, he founded and directed one of the largest retinal clinical research programs in the country in Central Florida participating as principal investigator in over 150 retinal clinical trials guiding several retinal drugs to global drug approvals such as Lucentis, Macugen, Eylea, and many others. He currently serves as the Chief Innovation/Technology Officer and Co-Founder of Aviceda Therapeutics, which is developing glyco-mimetics to modulate the immune system. He is an Associate Clinical Professor of Ophthalmology at University of Central Florida and serves on the board of Topology, True Blue Vision, Optamist, The Macula Store, Tolentino Eye Research Foundation and Panther Pharmaceuticals.

Aaron Osborne
Chief Medical Officer
Adverum Biotechnologies

Rishi Singh
Staff Physician, Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic Foundation & Professor of Ophthalmology, Lerner College of Medicine, Case Western Reserve University

Dr. Rishi P. Singh MD is a staff surgeon at the Cole Eye Institute, Cleveland Clinic and Professor of Ophthalmology at the Lerner College of Medicine in Cleveland Ohio. He also currently serves as the medical director of informatics at the Cleveland Clinic. He received his bachelors and medical degrees from Boston University and completed his residency at the Massachusetts Eye and Infirmary Harvard Combined Program in Boston, Massachusetts. Dr. Singh then completed a medical and surgical fellowship at the Cole Eye Institute in Cleveland,Ohio. He specializes in the treatment of medical and surgical retinal disease such as diabetic retinopathy, retinal detachment, and age-related macular degeneration. Dr. Singh has authored more than 170 peer reviewed publications, books, and book chapters and serves as the principal investigator of numerous national clinical trials advancing the treatment of retinal disease. Dr. Singh is the former president on the Retina World Congress and is a board member of the American Society of Retina Specialists. Dr. Singh has been honored with several research recognitions such as the Alpha Omega Alpha Research Award and American Society of Retina Specialists Senior Honor Award.

Day One

Wednesday, April 14th 2021

4:30 pm | Chair-Led Q&A: Targeting New Therapeutic Pathways & Looking Beyond Anti-VEGF

3:30 pm | Opening chair remarks

5:05 pm | Chair Led Q&A: Targeting New Therapeutic Pathways & Looking Beyond Anti-VEGF

Jason Ehrlich
Chief Medical Officer and Chief Development Officer
Kodiak Sciences

Dr. Ehrlich serves as Chief Medical Officer and Chief Development Officer at Kodiak.  Dr Ehrlich is internationally recognized for his leadership and expertise in ophthalmic drug development.  Prior to joining Kodiak, Dr. Ehrlich served in an executive capacity as Global Head, Clinical Ophthalmology at Genentech, a member of the Roche Group.  In roles of increasing responsibility at Genentech/Roche from 2008-2018, Dr. Ehrlich’s efforts as lead clinician for Lucentis in diabetic eye disease resulted in a unanimous FDA Advisory Committee vote and the first-ever FDA approval of an intraocular drug for diabetic macular edema.  He then championed filing of a collaborative group study to further expand the Lucentis labeling into all forms of diabetic retinopathy, resulting in another first-ever FDA approval that provided a new option for patients:  to be treated with anti-VEGF to achieve regression of their diabetic retinopathy disease.  Dr. Ehrlich guided the integration of the ophthalmic drug delivery company ForSIGHT VISION4 into Genentech/Roche after its acquisition, including oversight of the successful Phase II study of the ranibizumab Port Delivery System.  In his work, Dr. Ehrlich has participated in or overseen numerous sBLAs and both FDA and European health authority interactions. He led the global development of lampalizumab, including design and execution of the pivotal Phase III program that included over 1,800 patients, over 275 sites, and more than 20 countries.  He also oversaw his team’s effort to secure FDA approvals for Lucentis in its Prefilled Syringe and for choroidal neovascularization due to pathologic myopia and guided the successful transition to global Phase III development of Faricimab, a novel bispecific antibody for retinal vascular disease.  Dr. Ehrlich completed his Ophthalmology residency at Stanford University School of Medicine, earned his M.D. and Ph.D. degrees from Stanford through the NIH-funded Medical Scientist Training Program, and received his A.B. in Molecular Biology summa cum laude from Princeton University.

Day Two

Thursday, April 15th 2021

12:55 pm | Chair Led Q&A: Latest Case Studies Tackling the VEGF Pathway

12:30 pm | KSI-301: An antibody-biopolymer conjugate for extended durability in retinal diseases

John Greenwood
Professor of Biomedical Research, UCL Institute of Ophthalmology and Founding Scientist
PanAngium Therapeutics

Professor Greenwood trained in physiology at the Institute of Psychiatry, University of London, where his work focused on the structure and function of the blood-brain barrier (BBB) in health and disease. He then moved to the BBB group at King’s College London and after that was awarded the Renee Hock Fellowship at the Institute of Ophthalmology, London. In 2000 he was appointed to the Davson Chair of Biomedical Research and between 2008 and 2016 was Head of the Department of Cell Biology. The main focus of the Greenwood laboratory has been the investigation of the role the vasculature plays in the onset and progression of diseases such as uveitis, age-related macular degeneration, diabetic retinopathy, multiple sclerosis (MS), and cancer. The overarching aim of this work is to gain insight into the molecular mechanisms of the vasculature that contribute to the disease process, identify potential therapeutic targets, develop and test therapeutic strategies and eventually translate this into patient trials. Following the discovery and reporting in 2013 of a novel vasculopathic factor, leucine-rich alpha-2 glycoprotein 1 (LRG1), its potential as a therapeutic target in ocular disease and cancer has been investigated extensively. Upon conclusion of several major MRC funded translational awards, and with co-founder Professor Steve Moss, UCL Business spun out PanAngium Therapeutics to commercialise therapeutics targeting LRG1. Seed funding from UCL Technology Fund has funded pre-clinical development which in turn is now enabling a series A funding round for clinical development.

Day Two

Thursday, April 15th 2021

9:20 am | Chair Led Q&A: Targeting New Therapeutic Pathways & Looking Beyond Anti-VEGF

8:30 am | Targeting the novel vasculopathic factor LRG1 for treatment of retinal vascular dysfunction

Theresa Heah
Chief Medical Officer
AsclepiX Therapeutics, Inc.

Day Two

Thursday, April 15th 2021

10:20 am | AXT107, a self-forming gel depot peptide that inhibits VEGFR2 signaling and activates Tie2 signaling, and its Potential Role in Retinal Vascular Diseases

10:35 am | Chair Led Q&A: Targeting New Therapeutic Pathways & Looking Beyond Anti-VEGF

David Boyer
Senior Partner
Retina-Vitreous Associates Medical Group

David S. Boyer, M.D. is a Board-certified ophthalmologist specializing in the treatment of diseases of the retina and vitreous. He is Senior Partner at  Retina-Vitreous Associates Medical Group with offices in Los Angeles, Beverly Hills, North Hollywood, Torrance, Pasadena, Tarzana and Glendale, California.  Dr. Boyer is an Adjunct Clinical Professor of Ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, CA.  He has an extensive research background and is currently an investigator for various clinical trials. He is one of the leading retinal clinical researchers in the country for new treatments in macular degeneration and diabetic macular edema. A widely-published author and avid lecturer, Dr. Boyer lectures nationally and internationally on retinal research and the innovative approach to the treatment of retinal diseases.

Day One

Wednesday, April 14th 2021

8:40 am | Opening Remarks from the Chair

Szilard Kiss
Bob and Dolores Hope - Robert M. Ellsworth, M.D. Distinguished Associate Professor in Ophthalmology; Chief of the Retina Service
Weill Cornell Medicine

I received an undergraduate degree with honors from Columbia College, medical school training at Columbia University Vagelos College of Physicians & Surgeons and completed an ophthalmology residency and surgical vitreoretinal fellowship at Harvard Medical School and the Massachusetts Eye & Ear Infirmary, where I was selected by the faculty to serve as the Chief Retina Fellow. My research career started as an undergraduate at Columbia College where, in conjunction with the National Aeronautics and Space Administration (NASA) and the Department of Defense, I evaluated the implications of microgravity on early developmental patterning with scientific experiments launched on the space shuttle Discovery (STS-70) and the space shuttle Columbia (STS-78). I am currently the Associate Dean of Clinical Compliance, Chair of the General Faculty Council, Chief of the Retina Service, Director of Clinical Research, Director of Teleophthalmology, and the Bob and Dolores Hope - Robert M. Ellsworth, M.D. Distinguished Associate Professor in Ophthalmology at Weill Cornell Medical College. Currently, my clinical and translational research efforts focus on four broad areas: ocular gene and cellular therapy, novel therapeutic targets for ocular neovascularization, complex vitreoretinal surgical techniques, and retinal imaging. I have participated as a principal investigator in over three-dozen prospective clinical trials and laboratory investigations. I have authored over 280 scientific publications, given nearly 270 invited lectureships worldwide, and serve on the Editorial Board and as a scientific reviewer to a number of major journals. In addition to my scientific efforts, I have garnered a reputation as a world renowned medical and surgical vitreoretinal specialist; my clinical practice draws patients from all regions of the world. For my academic and clinical work, I have won numerous academic and scientific awards including the Schepens Eye Research Institute Joint Clinical Research Center Pilot Project Grant, the Heed Ophthalmic Foundation Fellowship Award, the Ronald G. Michels Foundation Fellowship Award, the Paul Kayser International Fellowship Award, American Society of Retina Specialists Rhett Buckler Award, and the Research to Prevent Blindness Physician-Scientist Award. For my contributions to ophthalmology, I have received the Honor and Senior Honor Awards from the American Society of Retina Specialists and the Honor Award from the American Academy of Ophthalmology. I was also among a select group of retina specialists worldwide (and the youngest) to be elected by my peers as a Charter Member of the Retina Hall of Fame. I have also been named to several regional, national and international Top Doctors lists, including The Ophthalmologist Power List Top 40 Under 40 Ophthalmologist Worldwide, Retina 150 Innovators in Medical and Surgical Retina, Castle Connolly’s Top Doctors, and New York Super Doctors.

Day Two

Thursday, April 15th 2021

12:00 pm | Opening Remarks from the Chair

Usha Chakravarthy
Professor of Ophthalmology and Vision Sciences
Queen's University Belfast

Usha Chakravarthy is Professor of Ophthalmology and Vision Sciences in the Queen’s University of Belfast. Her clinical interests lie in the management of retinal disorders and she has been the lead clinician for medical retina since her appointment.   She was appointed Clinical Director for Ophthalmology Services and lead clinician for Retina in the Belfast Trust and held senior positions until her phased retirement in 2017. She has a varied portfolio of research interests.   Her interest in research burgeoned and grew after she completed her PhD on the therapeutic potential of ionising radiation on intraocular cellular proliferation. Notably she undertook one of the first studies that characterised the proliferative potential of fibroblasts within the eye and modifications to their cell biology from exposure to ionising radiation.   She subsequently examined the  molecular expression of vasoactive peptides in the retina and profiled gene expression under conditions of simulated hyperglycemia in experimental using both in vitro and in vivo studies. She consolidated this work into clinical translational medicine for which she was awarded the Welcome University Award and Senior Clinical Lectureship and was appointed . Professor in Ophthalmology and Vision Science. Her  clinical research involves studies of retinal and choroidal vascular diseases and degenerative aging changes contributing to sight loss in older adults.  She is recognised internationally for her work on age-related macular degeneration and diabetic retinopathy their pathogenesis and key risk factors including gene and environment interactions and clinical management of these disorders.   She has in excess of 300 publications and many book chapters.  She was chairperson of the ophthalmology specialty group for UKCRN and the Royal College of Ophthalmologists Academic Group. On an international level she has served on innumerable scientific bodies and panels including the International AMD alliance, Laskar Foundation, the credentials and scientific committee of the macula society,  the awards committee member for the Association for Research and Vision in Ophthalmology,  the German Research Foundation, The French research Foundation, The Austrian Research Panel.  She has been on the editorial board of national and international journals and was a member of the oversight committee for  JAMA Ophthalmology . She  has delivered many eponymous and other invited lectures in the UK and abroad including the prestigious Paul Henkind lecture for the Macula Society, the Friedman lecture, Distinguished Professor National Eye Institute and the Wilmer Eye Institute John’s Hopkins The Bowman Lecture at the Royal College of Ophthalmologists and the Gass Award from the Macula society.   She is visiting Professor at the Singapore Eye Research Institute and recently appointed as visiting Professor Senior Global Medical Advisor for Roche.   She  continues to serve on advisory boards of several national and international governmental organisations.   In 2016 she was awarded the Alan Alderman award and Commander of the Order of the British Empire (CBE) for her services.

William Seiple
Chief Research Officer, Lighthouse Guild and Research; Professor, Department of Ophthalmology
New York University School of Medicine

Day One

Wednesday, April 14th 2021

10:15 am | Functional testing in clinical studies: MAIA Microperimetry

Carl Regillo
Chief of the Retina Service, Wills Eye Hospital; Partner, Mid Atlantic Retina; and Professor of Ophthalmology
Thomas Jefferson University

Day One

Wednesday, April 14th 2021

1:30 pm | Opening Remarks from Chair

Marion Munk
Professor, Managing Director, Bern Photographic Reading Center, University Hospital Bern; Adjunct Faculty, Dept of Ophthalmology, Northwestern University; Chief Medical Officer
Isarna Therapeutics

Prof. Marion R. Munk is a trained MD, PhD, and Uveitis and Medical Retina specialist at the University Clinic Bern in Switzerland and Managing Director at the Bern Photographic Reading Center. She is adjunct Faculty at the Northwestern University, Chicago, USA, Director of Eyegnos Consulting and Chief Medical Officer at Isarna Therapeutics. Marion is author of > 150 scientific articles and book chapters. Her major research interests cover image processing, image analyses, artificial intelligence, macular diseases and posterior uveitis. She is member of the Editorial Board of IOVS, Acta Ophthalmologica, Ocular Inflammation and Infection and BMC Ophthalmology and EyeNet and is providing peer-review for a long list of scientific journals within Ophthalmology.

Day One

Wednesday, April 14th 2021

4:40 pm | Targeting TGF-β2 with Antisense Oligonucleotides as a New Therapy for wet AMD and DME

5:05 pm | Chair Led Q&A: Targeting New Therapeutic Pathways & Looking Beyond Anti-VEGF

Workshop B

Tuesday, April 13th, 2021

3:00 pm | Biomarkers in Wet AMD

Michael Stewart
Professor and Chairman of Ophthalmology
Mayo Clinic Department of Ophthalmology, Jacksonville, FL

Michael W. Stewart, MD, is chairman of the Department of Ophthalmology and Professor of Ophthalmology at the Mayo Clinic in Jacksonville, Florida. Dr. Stewart graduated with honors in chemistry from Harvard College in Cambridge, Massachusetts, and from the McGill University Faculty of Medicine in Montreal, Quebec. He completed an ophthalmology residency at Emory University in Atlanta, Georgia, and two vitreoretinal fellowships Touro Infirmary in New Orleans, Louisiana and the University of California, Davis). He has published over 130 peer-review articles, 18 book chapters, and a monograph on the pharmacologic treatment of diabetic retinopathy. Dr. Stewart is on the editorial boards of several journals and is an Associate Editor of the American Journal of Ophthalmology. His research interests include diabetic retinopathy, macular degeneration, retinal vein occlusions, infectious retinitis, retinal pharmacology, pharmacokinetics, and the mathematical modeling of ocular treatments.

Day One

Wednesday, April 14th 2021

10:45 am | Panel Discussion: Ending the Burden of Monthly Treatments – Mechanisms to Increasing the Durability & Accessibility of Wet AMD & DME Therapeutics

Anat Loewenstein
Director Department of Ophthalmology, Tel Aviv Medical Center, Vice dean Sackler Faculty of Medicine
Tel Aviv University

Anat Loewenstein, MD, Professor of Ophthalmology, Vice Dean of the Faculty of Medicine, and Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at the Tel Aviv University, and the Chairman of the Division of Ophthalmology at the Tel Aviv Medical Center, President of the Israeli Ophthalmological Society. Main field of interest is the investigation of the drug administration and toxicity to the retina, early detection of macular degeneration and home monitoring of disease. Involved in the development of multiple innovative efforts, was the leader behind the development of novel technology for early detection of macular degeneration, the development of automated technology for detection of retinal disease activity and the development of augmented virtual reality to replace the operating microscope as well as development of home OCT. Published 435 papers in peer reviewed journals, and contributed multiple chapters to ophthalmology textbooks. Has multiple roles in the most prominent retina societies. Today, serves on the International committee of the macula society and is currently the General Secretary of the Euretina. Is active at most international retina meetings and is an invited speaker in most. Serves as the Editor in Chief of the Journal Case Reports in Ophthalmology, is an associate editor of the European Journal of Ophthalmology and of Ophthalmologica. Received multiple international awards, ss a leader in retina disease diagnosis and management and serves on the medical advisory boards of most prominent ophthalmological pharma and device companies. Has many roles as a leader in mentorship of young retina specialists including a mentorship educational program of ARVO, Euretina as well as mentorship programs supported by industry.

Workshop B

Tuesday, April 13th, 2021

2:30 pm | Retinal Fluid Volume as a Biomarker in NV-AMD

Francine Behar-Cohen
Founder & Chief Scientific Officer
Eyevensys

Day Two

Thursday, April 15th 2021

3:00 pm | Chair Led Q&A

1:30 pm | Dual Genes Combination Therapy for Improved Outcomes in Wet AMD

Sérgio Leal
Director, Global Clinical Leader
Bayer

Aaron Lee
Assistant Professor, Ophthalmology
University of Washington School of Medicine

Workshop B

Tuesday, April 13th, 2021

3:30 pm | Discovering Biomarkers for AMD Using Deep Learning

Michael Miller
Member of Scientific Advisory Board
Glycadia

Workshop B

Tuesday, April 13th, 2021

4:00 pm | Non-Enzymatic Glycation of Albumin May Induce Diabetic Retinopathy: Evidence for a Therapeutic Intervention

Eric Ng
Assistant Scientist, Schepens Eye Research Institute of Mass Eye and Ear; Assistant Professor of Ophthalmology, Department of Ophthalmology
Harvard Medical School

Workshop A

Tuesday, April 13th, 2021

10:10 am | Mouse Models of Experimental Choroidal Neovascularization

Claudio Punzo
Associate Professor, Dept. of Ophthalmology
University of Massachusetts Medical School

Workshop A

Tuesday, April 13th, 2021

12:00 pm | Unraveling Age-related Macular Degeneration

Faryan Tayyari
Research Scholar
University of Waterloo

Workshop A

Tuesday, April 13th, 2021

12:30 pm | Ocular Biomarkers: Tools for Discovery of Pathological Pathways and Validation of New Therapeutic Agents

William Schubert
Principal Scientist
Bayer

Workshop A

Tuesday, April 13th, 2021

10:00 am | Opening remarks from chair

Thomas Arno Albini
Professor of Clinical Ophthalmology
University of Miami Miller School of Medicine's Bascom Palmer Eye Institute

Thomas Arno Albini, MD, is Professor of Clinical Ophthalmology at the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute in Miami, FL, where he also serves as director of the vitreoretinal surgery fellowship. Dr Albini earned his MD from the Johns Hopkins University School of Medicine. He completed an ophthalmology residency at Doheny Eye Institute of the University of Southern California. He then completed a uveitis clinical and research fellowship at Doheny Eye Institute and a vitreoretinal surgery fellowship at Cullen Eye Institute of the Baylor College of Medicine.

Dr Albini's research interests include treatment and diagnosis of uveitis and macular disorders. He has recently published multiple papers on the risks of alternative, unproven “stem cell” therapies for eye disorders, leading to significant changes in US federal policy. He is a member of numerous professional and honorary societies, including the American Academy of Ophthalmology, the American Society of Retina Specialists, The Retina Society, the Macula Society, the Club Jules Gonin, the American Uveitis Society and the International Uveitis Study Group. He served as president of the Vit-Buckle Society and was Editor-in-Chief of the American Society of Retina Specialists' digital content. Dr. Albini has received numerous awards including the Senior Achievement Award from the American Academy of Ophthalmology and a Senior Honor Award from the American Society of Retina Specialists. He has authored over 130 peer-reviewed articles on clinical and experimental topics in vitreoretinal disease and uveitis.

Day Two

Thursday, April 15th 2021

1:25 pm | Opening Remarks from Chair

Casey Kopczynski
Chief Scientific Officer
Aerie Pharmaceuticals

Day One

Wednesday, April 14th 2021

2:55 pm | Chair Led Q&A: Making Strides Forward in Drug Delivery & Dosing

2:05 pm | PRINT Drug Delivery Technology: Bringing Rho Kinase Inhibition to Retinal Vascular Diseases

Kevin Peters
Chief Scientific & Medical Officer & Senior Vice President
Aerpio Pharmaceuticals

Dr. Peters guided the early preclinical and clinical development of Aerpio’s VE-PTP targeted Tie2 activators, and currently leads scientific discovery and translational development for Aerpio. He was formerly the Group Medical Director, CV and Metabolic Disease in Global and Discovery Medicine at Bristol Myers Squibb and head of Therapeutic Angiogenesis research at Proctor & Gamble Pharmaceuticals. Prior to that, Dr. Peters was an Associate Professor of Medicine and Pharmacology in the Division of Cardiology at Duke University Medical Center. Dr. Peters received his M.D. from the University of Iowa and was a Research Fellow and Adjunct Professor at the University of California, San Francisco. Dr. Peters has published broadly in the areas of growth factor receptor signaling and vascular biology and has led several preclinical programs to clinical proof of concept in vascular and metabolic diseases.

Day One

Wednesday, April 14th 2021

4:30 pm | Chair-Led Q&A: Targeting New Therapeutic Pathways & Looking Beyond Anti-VEGF

4:05 pm | Targeting the Tie2 Pathway for Vision Threatening Retinopathy

Victor Chong
Global Head of Medicine, Retinal Health
Boehringer Ingelheim

Day One

Wednesday, April 14th 2021

10:00 am | Chair Led Q&A: Ensuring Clinical Success for the Emerging Therapeutic Approaches in the Management of Wet AMD & DME

9:15 am | Future Directions to Address Unmet Clinical Need in the Treatment of Diabetic Macular Edema; How to Define NonResponder in DME? Is It Real or is There Something Else Going On?

Thomas Ciulla
Chief Medical Officer & Chief Development Officer
Clearside BioMedical

Day One

Wednesday, April 14th 2021

2:55 pm | Chair Led Q&A: Making Strides Forward in Drug Delivery & Dosing

1:40 pm | Suprachoroidal Drug Delivery & CLS-AX: A Potential Solution for Treatment Burden

10:45 am | Panel Discussion: Ending the Burden of Monthly Treatments – Mechanisms to Increasing the Durability & Accessibility of Wet AMD & DME Therapeutics

Peter Kaiser
Chaney Family Endowed Chair in Ophthalmology Research and Prof of Ophthalmology
Cleveland Clinic Lerner College of Medicine and Cole Eye Institute

Peter K. Kaiser, M.D. is the Chaney Family Endowed Chair for Ophthalmology Research and a Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine. He graduated magna cum laude with Highest Honors from Harvard College and magna cum laude from Harvard Medical School. He completed an internal medicine internship at Massachusetts General Hospital, an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute before joining the vitreoretinal department of the Cole Eye Institute at the Cleveland Clinic, Cleveland, Ohio. As a RO1 NIH-funded investigator, Dr. Kaiser leads a team involved in the evaluation of vascular biology in AMD and diabetic retinopathy. He is director of the Cole Center for ocular Research and Evaluation (CORE). In addition, Dr Kaiser is actively involved in clinical research as Study Chairman of 7 major, multi-center, international clinical trials, and principal investigator in over 60 trials evaluating new treatments for AMD, diabetic retinopathy, and other retinal disorders. He is the founder and director of the Digital Optical Coherence Tomography Reading Center (DOCTR). Complementing his research endeavors, Dr. Kaiser serves on numerous scientific advisory boards and addresses his research interests as an invited speaker at national and international conferences. He is a major contributor to the medical literature having authored 7 textbooks, and more than 400 peer-reviewed papers. He is Editor-in-Chief of Retinal Physician, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of Retina, Retina Today, and Ocular Surgery News. Dr. Kaiser has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with both Achievement and Senior Achievement Awards, and is listed as one of the “Best Doctors in America.” He is the team ophthalmologist for the Cleveland Cavaliers (National Basketball Association).

Day One

Wednesday, April 14th 2021

10:00 am | Chair Led Q&A: Ensuring Clinical Success for the Emerging Therapeutic Approaches in the Management of Wet AMD & DME

8:50 am | Opening Presentation: Evaluating the Unmet Clinical Need in the Angiogenesis-Driven Diseases, Neovascular/Wet Age-Related Macular Degeneration (AMD) & Diabetic Macular Edema (DME)

SriniVas Sadda
President & Chief Scientific Officer
Doheny Eye Institute

SriniVas R. Sadda, MD, is the President and Chief Scientific Officer of the Doheny Eye Institute, the Stephen J. Ryan – Arnold and Mabel Beckman Endowed Chair, and Professor of Ophthalmology at the University of California – Los Angeles (UCLA), David Geffen School of Medicine. He received his medical degree from The Johns Hopkins University in Baltimore, Maryland. After an internship at the William Beaumont Hospital in Royal Oak, Michigan, he returned to Johns Hopkins University and the Wilmer Eye Institute in Baltimore for an ophthalmology residency as well as neuro-ophthalmology and medical retina fellowships. Dr Sadda’s major research interests include automated retinal image analysis, retinal substructure assessment, advanced retinal imaging technologies, and vision restoration approaches. His research has been consistently funded by the National Institutes of Health (NIH) and multiple private organizations including the Foundation Fighting Blindness, Research to Prevent Blindness, Foundation for Retinal Research, and the Macula Vision Research Foundation. He has organized multiple consensus efforts for the classification of various retinal disorders. Dr. Sadda has served as Principal Investigator for over 30 major clinical trials, and has led several international collaborative research programs. He is the founder and Emeritus Director of the Doheny Image Reading Center, one of the largest centralized reading centers in the world. He has more than 550 publications in peer-reviewed journals and over 300 published abstracts. He authored the first edition of the textbook Emerging Technologies in Retinal Disease, as well as 20 other book chapters. As an invited lecturer, he has given more than 450 presentations around the country and the world, including multiple named lectures. Dr. Sadda also serves as an editorial board member of Ophthalmic Surgery, Lasers & Imaging, Retina, Graefe’s Archive for Clinical and Experimental Ophthalmology, Ophthalmology Retina, and Ophthalmology. He is also an editor of the 5th edition of the Ryan’s Retina textbook.  He regularly serves the NIH Center for Scientific Review on study section. Among Dr. Sadda’s awards and honors are a Research to Prevent Blindness Physician-Scientist Award, a Senior Honor Award from the American Society of Retina Specialists, a Senior Achievement Award and Secretariat Award from the American Academy of Ophthalmology, John H. Zumberge Research and Innovation Award, the Macula Society Young Investigator Award, Asia-Pacific Academy of Ophthalmology (APAO) Achievement Award, The Macula Society Paul Henkind Lecture and Award, and American Society of Retina Specialists Young Investigator Award. He has also received the Silver Fellow designation from the Association for Research in Vision and Ophthalmology. He has been named to the Best Doctors of America list for several consecutive years.

Day Two

Thursday, April 15th 2021

2:30 pm | Progress in Ophthalmic Imaging for Development of Biomarkers & Clinical Endpoints

3:00 pm | Chair Led Q&A

11:10 am | Panel: Searching for Novel Therapeutic Targets – Addressing Developmental Challenges for New Drug Candidates in Wet AMD & DME

Workshop B

Tuesday, April 13th, 2021

4:30 pm | How Biomarker Research Can Improve Our Understanding of the Pathology of These Conditions

Pooya Hemani
Healthcare Equity Analyst
Edison Group

Day Two

Thursday, April 15th 2021

11:10 am | Panel: Searching for Novel Therapeutic Targets – Addressing Developmental Challenges for New Drug Candidates in Wet AMD & DME

Thierry Bordet
Chief Scientific Officer
Eyevensys

Alan Franklin
Chief Executive Officer
ForwardVue Pharma

Dr. Alan Franklin is Founder of ForwardVue Pharma. He has performed 40,000+ intravitreal injections as a practicing retina specialist with over 20 years of experience. Dr. Franklin has served as principle investigator in a number of diabetic retinopathy and AMD trials, presents his work internationally and published multiple manuscripts on candidate molecules to treat these diseases. He was recognized for best research by the Association of University Professors in Ophthalmology meeting for his work on a novel anti-angiogenic compound. His other area of expertise is surgical visualization. Dr. Franklin is globally recognized for his publications and lectures on 3D Digitally Assisted Vitreoretinal Surgery and was recently awarded most watched video in 2019 by Retina Link Global for work on color channels. He also serves on several surgical visualization and development advisory boards. Dr. Franklin completed his clinical training at University of Iowa Hospitals and Clinics for vitreoretinal diseases and surgery. While at University of Iowa, Dr. Franklin secured both HEED and HEED-Knapp scholarships. Prior to that, he did ophthalmology residency at Saint Louis University where he was chief resident in 1996-1997. He attended medical school at the Medical College of Ohio/University of Toledo. After graduating medical school, Dr. Franklin earned a PhD at Vanderbilt University in the Department of Molecular Physiology and Biophysics. His thesis focused upon the molecular biology and cell type specific gene expression in the insulin producing cells of the pancreatic islet. Dr. Franklin continued his training at Vanderbilt as a Medical Intern, and ultimately completed his thesis during internship and residency. As an undergraduate at Northwestern University he obtained a Bachelor of Science in Biomedical Engineering and earned a letter in Varsity Track. Dr. Franklin is a member of the Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Society of Retina Specialists and the European Society of Retina Specialists

Day One

Wednesday, April 14th 2021

4:30 pm | Chair-Led Q&A: Targeting New Therapeutic Pathways & Looking Beyond Anti-VEGF

3:40 pm | ForwardVue Pharma: Long-Acting Therapeutics For Retinal Diseases

10:45 am | Panel Discussion: Ending the Burden of Monthly Treatments – Mechanisms to Increasing the Durability & Accessibility of Wet AMD & DME Therapeutics

Anne Fung
Global Development Lead, PDS
Genentech

Day One

Wednesday, April 14th 2021

12:30 pm | Chair Led Q&A; Making Strides Forward in Drug Delivery & Dosing

11:40 am | Port Delivery System with Ranibizumab: Developing the First Global Surgery, Device, Drug Combination Product for AMD & DME

Hugh Lin
Global Development Leader – Faricimab
Genentech

Day Two

Thursday, April 15th 2021

12:55 pm | Chair Led Q&A: Latest Case Studies Tackling the VEGF Pathway

12:05 pm | Faricimab: Developing a Ophthalmologic Bispecific Therapeutic for AMD & DME

Ashwath Jayagopal
Executive Director - Discovery Medicine
Kodiak Sciences

Ash Jayagopal is the Executive Director of Discovery Medicine at Kodiak Sciences in Palo Alto, California, where his team is developing the pipeline for therapy of retinal diseases including AMD, DR, and glaucoma.  These programs leverage Kodiak’s expertise in biopolymers, bioconjugates, and engineering of small and large molecule therapeutic modalities.  Dr. Jayagopal’s expertise includes drug and biomarker discovery for retinal diseases, as well as the development of clinically-relevant technologies for retinal imaging and drug delivery.  Prior to Kodiak, he was the Head of Molecular Pharmacology and Biomarkers in the Ophthalmology Division at Pharma Research and Early Development (pRED), F. Hoffmann - La Roche Ltd., in Basel, Switzerland, where his team developed several therapies now in clinical development for retinal diseases.  Prior to Roche, he was an NIH-funded Assistant Professor in the Departments of Ophthalmology and Visual Sciences at the Vanderbilt Eye Institute, and Molecular Physiology and Biophysics of Vanderbilt University Medical Center in Nashville, TN.  Dr. Jayagopal received his undergraduate (with honors) and doctoral degrees in Biomedical Engineering from Vanderbilt University, as well as an MBA from Indiana University (Kelley School of Business).  He has received the Roche Key Contributor Award, the Dolly Green Special Scholar Award from Research to Prevent Blindness, and a Junior Faculty Award from the American Diabetes Association for his research.

Day Two

Thursday, April 15th 2021

12:55 pm | Chair Led Q&A: Latest Case Studies Tackling the VEGF Pathway

12:30 pm | KSI-301: An antibody-biopolymer conjugate for extended durability in retinal diseases

11:10 am | Panel: Searching for Novel Therapeutic Targets – Addressing Developmental Challenges for New Drug Candidates in Wet AMD & DME

8:20 am | Opening Remarks from the Chair

Adnan Tufail
Professor - Ophthalmology
Moorfields Eye Hospital

Workshop B

Tuesday, April 13th, 2021

2:00 pm | Data Needed to Support Biomarker Qualification and Validation

Kapil Bharti
Senior Investigator – Ocular and Stem Cell Translational Research Section
National Institute of Health Sciences

Day Two

Thursday, April 15th 2021

11:10 am | Panel: Searching for Novel Therapeutic Targets – Addressing Developmental Challenges for New Drug Candidates in Wet AMD & DME

Workshop A

Tuesday, April 13th, 2021

11:00 am | 3D Tissue Engineered Models of wet-AMD and DME Derived from Patient-specific Stem Cells

Quintus Medley
Associate Director - Ophthalmology
Novartis

Day Two

Thursday, April 15th 2021

9:20 am | Chair Led Q&A: Targeting New Therapeutic Pathways & Looking Beyond Anti-VEGF

8:55 am | Effects of Inflammatory Cytokines & Dexamethasone on the Retina; Targeting Inflammatory Pathways That Offer a VEGF Independent Mechanism

Kerrie Brady
Chief Executive Officer
Occuterra Therapeutics

Day One

Wednesday, April 14th 2021

12:30 pm | Chair Led Q&A; Making Strides Forward in Drug Delivery & Dosing

12:05 pm | Non-Invasive Patient Self-Administration - Expanding Therapeutic Options for Patients With Earlier Stage Disease; Making Strides Forward in Drug Delivery & Dosing

Arun Upadhyay
Senior Director & Head of Discovery
Ocugen

Day Two

Thursday, April 15th 2021

10:35 am | Chair Led Q&A: Targeting New Therapeutic Pathways & Looking Beyond Anti-VEGF

9:30 am | Innovative Therapeutic For DME/DR & Wet-AMD: Fusion Of Novel Target & Delivery Approaches; OCU200: A novel Therapeutic For DME/DR & Wet-AMD

Grace Chang
Chief Medical Officer
Oxurion

Day Two

Thursday, April 15th 2021

11:10 am | Panel: Searching for Novel Therapeutic Targets – Addressing Developmental Challenges for New Drug Candidates in Wet AMD & DME

10:35 am | Chair Led Q&A: Targeting New Therapeutic Pathways & Looking Beyond Anti-VEGF

9:55 am | New Therapeutics Target RGD Integrins And The Plasma Kallikrein System: Overview Of First Clinical Findings

Steve Pakola
Chief Medical Officer
REGENXBIO

Day One

Wednesday, April 14th 2021

2:55 pm | Chair Led Q&A: Making Strides Forward in Drug Delivery & Dosing

2:30 pm | Utilizing Gene Therapy to Induce Long Term Treatment of Wet AMD & DME

10:45 am | Panel Discussion: Ending the Burden of Monthly Treatments – Mechanisms to Increasing the Durability & Accessibility of Wet AMD & DME Therapeutics

Moreno Menghini
Head of Department of Ophthalmology, Ospedale Regionale di Lugano, Switzerland; and Chief Medical Officer
Endogena Therapeutics

Day Two

Thursday, April 15th 2021

3:00 pm | Chair Led Q&A

2:00 pm | Predictive OCT Findings for Poor Responders to Anti-VEGF Therapy; Identifying Non-Responders to Current Clinical Standard-of-Care & Stratifying Patient Populations for Clinical Trial Programs

Christine Curcio
Professor – Ophthalmology & Director – Age-Related Maculopathy Histopathology Lab
University of Alabama at Birmingham

Christine A. Curcio PhD is White-McKee Endowed Professor of Ophthalmology and Visual Sciences at the University of Alabama at Birmingham School of Medicine (Birmingham, Alabama, USA). She collaborates with innovative eye banks to investigate human retinal neuroscience, aging, and age-related macular degeneration (AMD). She has focused on pathobiology (especially drusen and outer retinal degeneration) and validation of clinical retinal imaging technology, including optical coherence tomography, fundus autofluorescence, and adaptive optics-assisted outer retinal imaging. Her maps of the human photoreceptor layer provided a basis for rod-mediated dark adaptometry as a functional test for AMD. Since 1984, research resulting in ~200 peer review articles and >250 invited presentations has been funded by the National Institutes of Health, foundations, and industry. She serves on editorial boards of Investigative Ophthalmology & Visual Science and Retina. She was awarded the 2002 (inaugural) Roger H. Johnson Prize for Macular Degeneration research, the 2014 Ludwig von Sallmann Prize, and the 2020 Research to Prevent Blindness – David F. Weeks Award for excellence in AMD research. Dr. Curcio provides histology to the Classification of Atrophy group, a clinical international consensus group that is defining OCT-based imaging endpoints for AMD clinical trials. Collaborative clinicopathologic correlation with K.B. Freund MD has validated imaging of retinal neovascularization morphologies.

Day One

Wednesday, April 14th 2021

10:00 am | Chair Led Q&A: Ensuring Clinical Success for the Emerging Therapeutic Approaches in the Management of Wet AMD & DME

9:35 am | Two Ways to Achieve Clinical Success: Two Vascular Systems of the Retina